Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron

Vito Lorusso National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy Abstract: As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV) requires the combination of 5-HT3 receptor antagonist (RA) with an...

Full description

Bibliographic Details
Main Author: Lorusso V
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:Therapeutics and Clinical Risk Management
Subjects:
NEPA
netupitant
NK1
CINV
vomiting
risk factors
Online Access:https://www.dovepress.com/management-of-chemotherapy-induced-nausea-and-vomiting-by-risk-profile-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/management-of-chemotherapy-induced-nausea-and-vomiting-by-risk-profile-peer-reviewed-article-TCRM

Similar Items